GlassScriptPhysician profile
Ismael Mercado
NPI 1376521997
$7,395.10
in general payments reported to CMS, 2019-2025
26 companies · $636 in 2025
The $636 reported for 2025 was more than what 87% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,027 · 2020: $886 · 2021: $1,029 · 2022: $1,336 · 2023: $713 · 2024: $768 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,576.23 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $1,043.46 | 2019-2025 | Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $728.88 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $690.23 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $437.80 | 2019-2023 | Xarelto |
| Abbvie INC. | $424.70 | 2022-2024 | |
| Biocryst US Sales Co., LLC | $349.62 | 2023-2024 | Orladeyo |
| Novo Nordisk INC | $216.97 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $135.68 | 2021 | |
| Pfizer Pharmaceuticals LLC | $123.51 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.08 | 2022 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $120.00 | 2019-2021 | |
| Dexcom, INC. | $118.35 | 2021 | |
| Acadia Pharmaceuticals INC | $117.57 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $114.30 | 2025 | Crexont |
| Pfizer INC. | $112.59 | 2022-2025 | |
| Glaxosmithkline, LLC. | $105.07 | 2019-2020 | |
| Amgen INC. | $99.60 | 2022 | |
| Becton, Dickinson and Company | $73.55 | 2025 | Rotarexs 6 F X 135 Cm |
| Eisai INC. | $50.00 | 2021 | |
| Pbg Puerto Rico LLC | $43.00 | 2019-2020 | |
| Verity Pharmaceuticals INC. | $25.17 | 2025 | Tlando |
| Exact Sciences Corporation | $25.00 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $18.18 | 2021 | |
| Boston Scientific Corporation | $17.65 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ismael Mercado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.